业绩持续恶化，长生人寿艰难求生

Core Viewpoint - In 2025, despite a favorable overall performance in the insurance industry, Changsheng Life Insurance Company reported significant losses, raising concerns about its solvency and operational challenges [1][3]. Financial Performance - Changsheng Life achieved insurance business revenue of 1.926 billion yuan in 2025, a year-on-year decrease of 32.39% [6]. - The company reported a net loss of 512 million yuan in 2025, worsening from a loss of 192 million yuan in 2024 [6]. - As of the end of Q4 2025, the core solvency adequacy ratio was 64.8%, and the comprehensive solvency adequacy ratio was 79.7%, both below regulatory standards [3][4]. Regulatory Compliance - According to regulatory requirements, insurance companies must maintain a core solvency adequacy ratio of at least 50% and a comprehensive solvency adequacy ratio of at least 100% to be considered compliant [3]. - Changsheng Life's solvency ratios are close to the regulatory red line, with the comprehensive ratio significantly below the required threshold [3]. Capital Supplementation Efforts - The company is actively pursuing capital supplementation to improve its solvency situation, with shareholders accelerating related arrangements [4][5]. - The last capital increase occurred in July 2015, raising registered capital from 1.3 billion yuan to 2.167 billion yuan [5]. Investment Challenges - In 2025, Changsheng Life faced significant investment losses, including a 290 million yuan impairment on a real estate debt investment project, which negatively impacted its solvency ratios [7]. - The company has reported multiple investment losses in recent years, including impairments of 80 million yuan and 95 million yuan on two investment projects disclosed in the Q4 2024 solvency report [7]. Strategic Initiatives - To address its financial challenges, Changsheng Life plans to enhance profitability and reduce losses through various strategies, including optimizing asset allocation towards fixed-income investments and improving new business sales [8].